Agent | Mechanism of action | Target type and therapeutic purpose | ClinicalTrials.gov identifier | Status | Â |
---|---|---|---|---|---|
Plasma exchange with albumin 1 immunoglobulin | Plasma exchange | Remove amyloid | NCT01561053 | Completed | Â |
ALZT-OP1a + ALZT-OP1b | Mast cell stabilizer, anti-inflammatory | Amyloid-related and antineuroinflammatory | NCT02547818 | Active, not recruiting |  |
ANAVEX2–73 | Anti-tau, Anti-amyloid | Anti-tau, anti-amyloid, and antineuroinflammatory | NCT03790709 | Recruiting |  |
Crenezumab | Monoclonal antibody directed at oligomers | Remove amyloid | NCT02670083.NCT03114657.NCT03491150 | Completed | Â |
E2609 (elenbecestat) | BACE inhibitor | Reduce amyloid production | NCT02956486.NCT03036280 | Active, not recruiting | Â |
Gantenerumab | Monoclonal antibody | Remove amyloid | NCT02051608.NCT01224106.NCT03444870.NCT03443973 | NCT02051608.NCT01224106 Active, not recruiting, NCT03444870.NCT03443973 Recruiting | Â |
Gantenerumab and Solanezumab | Monoclonal antibody | Remove amyloid/reduce amyloid production | NCT01760005 | Recruiting | Â |
GV-971 (sodium oligomannurarate) | Aβ aggregation inhibitor | Amyloid-related | NCT02293915 | Completed |  |
Solanezumab | Monoclonal antibody | Remove amyloid and prevent aggregation | NCT02008357 | Active, not recruiting | Â |